1,386 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Bought by Ethos Financial Group LLC

Ethos Financial Group LLC acquired a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,386 shares of the medical research company’s stock, valued at approximately $328,000.

A number of other large investors have also recently bought and sold shares of the company. TimesSquare Capital Management LLC bought a new position in shares of Charles River Laboratories International in the 4th quarter valued at $7,526,000. Picton Mahoney Asset Management grew its position in Charles River Laboratories International by 34.1% in the fourth quarter. Picton Mahoney Asset Management now owns 905 shares of the medical research company’s stock valued at $213,000 after acquiring an additional 230 shares during the last quarter. Everpar Advisors LLC acquired a new position in Charles River Laboratories International during the fourth quarter worth about $918,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Charles River Laboratories International by 4.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 513,227 shares of the medical research company’s stock worth $121,327,000 after acquiring an additional 21,028 shares during the last quarter. Finally, Apollon Wealth Management LLC boosted its stake in shares of Charles River Laboratories International by 24.7% in the 4th quarter. Apollon Wealth Management LLC now owns 1,287 shares of the medical research company’s stock valued at $304,000 after purchasing an additional 255 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, VP William D. Barbo sold 4,050 shares of the stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the transaction, the vice president now directly owns 22,879 shares in the company, valued at approximately $5,685,431.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, EVP Victoria L. Creamer sold 5,000 shares of the business’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the completion of the sale, the executive vice president now directly owns 13,550 shares of the company’s stock, valued at approximately $3,437,635. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP William D. Barbo sold 4,050 shares of the stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total value of $1,006,425.00. Following the completion of the transaction, the vice president now owns 22,879 shares in the company, valued at approximately $5,685,431.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,932 shares of company stock valued at $3,693,663. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Trading Down 2.2 %

NYSE:CRL traded down $5.18 on Thursday, reaching $230.11. 1,004,419 shares of the stock traded hands, compared to its average volume of 548,995. The firm has a market capitalization of $11.85 billion, a price-to-earnings ratio of 24.98, a price-to-earnings-growth ratio of 1.83 and a beta of 1.44. Charles River Laboratories International, Inc. has a 1-year low of $161.65 and a 1-year high of $275.00. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73. The company’s 50 day moving average is $250.70 and its 200-day moving average is $225.27.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.07. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. Charles River Laboratories International’s revenue for the quarter was down 7.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.98 earnings per share. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CRL has been the subject of a number of research analyst reports. TheStreet upgraded shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a research report on Friday, March 1st. Guggenheim cut Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. Argus raised their price objective on Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a report on Monday, March 18th. UBS Group increased their target price on Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday, February 15th. Finally, Evercore ISI boosted their price target on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.23.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).